Symphogen taps Gallus for CMO work; WuXi, Clinipace name new execs;

> Symphogen has selected Gallus BioPharmaceuticals to manufacture antibody candidates for clinical trials. News

> WuXi PharmaTech ($WX) has appointed Hua Mu to serve as vice president of operations and head of product development. Mu has served stints at Roche ($RHHBY), Biogen Idec ($BIIB) and China's Hutchison MediPharma. More

> Clinipace has picked Lee Schacter to be its next executive medical director, bringing experience from Johnson & Johnson ($JNJ), AstraZeneca ($AZN) and Pfizer ($PFE). Item